Results 181 to 190 of about 989 (256)
Deep phenotyping of heart failure with preserved ejection fraction through multi‐omics integration
European Journal of Heart Failure, EarlyView.Deep phenotyping of of heart failure with preserved ejection fraction (HFpEF) through multi‐omics integration. AI, artificial intelligence. Aims
Heart failure with preserved ejection fraction (HFpEF) has become the predominant form of heart failure and a leading cause of global cardiovascular morbidity and mortality.Jakob Versnjak, Titus Kuehne, Pauline Fahjen, Nina Jovanovic, Ulrike Löber, Gabriele G. Schiattarella, Nicola Wilck, Holger Gerhardt, Dominik N. Müller, Frank Edelmann, Philipp Mertins, Roland Eils, Michael Gotthardt, Sofia K. Forslund, Benjamin Wild, Marcus Kelm +15 morewiley +1 more sourceEuropean Journal of Heart Failure expert consensus statement on transcatheter treatment of mitral regurgitation in heart failure
European Journal of Heart Failure, EarlyView.The patient with SMR: From diagnostic assessment to treatment. Secondary mitral regurgitation (SMR) is highly prevalent in patients with heart failure (HF), associated with poor prognosis, and its treatment is typically preceded by implementing pharmacotherapy for HF as well as cardiac resynchronization therapy.Christos Iliadis, Marianna Adamo, Volker Rudolph, Nicole Karam, Ralph Stephan von Bardeleben, Stefan D. Anker, Victoria Delgado, Jörg Hausleiter, Hannah Kempton, Marco Metra, Michael Böhm, Stephan Baldus +11 morewiley +1 more sourceInterplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS‐HF
European Journal of Heart Failure, EarlyView.CV, cardiovascular, HF, heart failure; K+, serum potassium; eGFR, estimated glomerular filtration rate. Aims
Finerenone improved heart failure (HF) outcomes in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Clinical decision‐making around initiation of mineralocorticoid receptor antagonists often relies on João Pedro Ferreira, Muthiah Vaduganathan, Brian L. Claggett, Ian Kulac, John W. Ostrominski, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Bertram Pitt, Katja Rohwedder, Meike Brinker, Patrick Schloemer, John J. V. McMurray, Scott D. Solomon, Faiez Zannad +17 morewiley +1 more sourceEuropean Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action
European Journal of Heart Failure, EarlyView.Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects. Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla +24 morewiley +1 more sourceNeutrophil‐to‐lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum
European Journal of Heart Failure, EarlyView.Illustration defining the criteria for high‐risk acute myocarditis (AM), incorporating haemodynamic compromise, life‐threatening arrhythmias, and reduced left ventricular ejection fraction (LVEF <40%). Neutrophil‐to‐lymphocyte ratio (NLR) ≥4 is an independent risk marker, including among patients with preserved LVEF (≥50%) at presentation, where ...Cristina Madaudo, Amitai Segev, Emanuele Bobbio, Chiara Baggio, Jonathan Schütze, Piero Gentile, Marta Sanguineti, Luca Monzo, Matteo Schettino, Emma Ferone, Ahmed Elsanhoury, Anan Younis, Matteo Palazzini, Adriana Ferroni, Valentina Giani, Matthew Sadler, Mohammad Albarjas, Leonardo Calò, Christian Lars Polte, Andrea Garascia, Stefano Figliozzi, Paul A. Scott, Ajay M. Shah, Alfredo Ruggero Galassi, Mauro Giacca, Gianfranco Sinagra, Entela Bollano, Theresa McDonagh, Carsten Tschöpe, Giuseppina Novo, Enrico Ammirati, Roy Beigel, Christoph Gräni, Marco Merlo, Pietro Ameri, Antonio Cannata, Daniel I. Bromage, CAIR Collaboration +37 morewiley +1 more sourceChlorothiazide is associated with a weaker diuretic response than furosemide in infants with bronchopulmonary dysplasia (BPD) [PDF]
Timothy D. Nelin, Matthew Huber, Heidi Morris, Erik A. Jensen, Kathleen Gibbs, Sara B. DeMauro, Avery W. Zierk, Nelson Lee Novick, David M. Rub, A. Lawin O'Brien, Scott A. Lorch, Nicolas A. Bamat +11 moreopenalex +1 more sourceArtificial intelligence‐based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis
European Journal of Heart Failure, EarlyView.Artificial intelligence (AI)‐based estimation of stroke volume for risk prediction in amyloid transthyretin cardiomyopathy (ATTR‐CM). ATTRv, hereditary transthyretin amyloidosis; ATTRwt, wild‐type transthyretin amyloidosis; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; LVOT‐VTI, left ventricular outflow tract velocity‐time ...Lucia Venneri, Alberto Aimo, Aldostefano Porcari, Irem Sezer, Adam Ioannou, Awais Sheikh, Josephine Mansell, Yousuf Razvi, Surabhi Bhaskar Iyer, Ana Martinez‐Naharro, Francesco Bandera, Sze Chi Lim, Matthew Frost, Justin Ezekowitz, Carolyn S.P. Lam, William Moody, Carol Whelan, Helen Lachmann, Ashutosh Wechelakar, Michele Emdin, Philip N. Hawkins, Scott David Solomon, Julian D. Gillmore, Marianna Fontana +23 morewiley +1 more source